Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 10;55(1):2189295. doi: 10.1080/07853890.2023.2189295

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 5. — GC with GPC3^high CAFs is correlated with lower response of PD-1 blockage therapy. (A) The likelihood of the clinical response to anti-PD-1 therapy for high and low GPC3 expression GC patients from the TCGA cohorts. True represents immunotherapy responders, while false represents immunotherapy nonresponders. (B–D) The violin plots present of TIDE value, immune dysfunction and immune exclusion in high and low GPC3 expression GC patients. (E) The relationship between different GPC3 expression in CAFs and the response ratio of anti-PD-1 therapy in GC patients. (F–I) The proportion of interferon (IFN)-γ-positive cells of CD4+ or CD8+ T cells in the tumours with different GPC3 expression in CAFs.